openPR Logo
Press release

Creative Diagnostics Broadens Its Portfolio with New Pseudotyped GFP HPV

06-03-2021 09:12 AM CET | Science & Education

Press release from: Creative Diagnostics

As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently introduces new Pseudotyped GFP HPV for immunogenicity assessment in vaccine trials. This new series of HPV reporter virus particles can be used for measuring neutralizing anti-HPV antibodies in pseudovirion-based neutralization assays.

Human papillomaviruses (HPVs) are double-stranded non-enveloped DNA viruses that infect keratinocytes of stratified squamous epithelia. Immunogenicity assessments in vaccine trials have focused on measurements of antibody responses to the vaccine. Currently, the "gold standard" for measuring neutralizing anti-HPV antibodies is the pseudovirion-based neutralization assay (PBNA). Instead of using authentic viruses, pseudovirions with an encapsidated reporter can be used to avoid high risks and provide more direct measurements for antibodies.

Creative Diagnostics Pseudotyped GFP HPV production is based on the transfection of a 293 cell line, 293FT, engineered to express high levels of SV40 large T antigen. The cells are co-transfected with codon-modified papillomavirus capsid genes, L1 and L2, together with a pseudogenome plasmid containing the SV40 origin of replication. Pseudovirus (PsV) encapsidating a GFP reporter plasmid can be used to develop a high-throughput in vitro neutralization assay in a 96-well plate format.

In this release, various products are introduced to the research community, such as the Pseudotyped GFP HPV6 (Cat. No PSVG-HPV6), which is used to test the ability of serum and antibodies to neutralize the infectivity of HPV6. HPV6 Pseudoviruses are produced in 293FT cells using three separate plasmids, encoding the HPV L1 protein, the HPV L2 protein, and a reporter gene. HPV6 Pseudovirus display antigenically correct L1 and L2 protein pseudotyped on replication-incompetent virus particles. Pseudoviruses are capable of a single round of infection and carry a plasmid that expresses GFP optical reporter gene upon infection.

"HPVs compose a group of more than 100 genotypes that can cause cervical cancer and its precursor lesions. At present 12 types of HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) have been classified as carcinogenic types to humans and an additional 8 types are classified as possibly carcinogenic types to human. We can provide up to 15 different types of HPV pseudovirus, which include all 12 carcinogenic HPV types." said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics.

"In addition to the Pseudotyped GFP HPV, Creative Diagnostics has established a global-leading virus-like particles (VLPs) manufacturing platform using an E. coli cell system. With years of exploration, our scientists have successfully obtained various highly purified HPV VLPs, which can be typically used for antibody discovery, diagnostic reagent development, and vaccine development. Our products have significantly contributed to HPV vaccine-related research. We'll be glad to work with you to solve your challenges." said Prof. Mike Knuth, M.D., the chief scientific officer of R&D department of Creative Diagnostics.

If you want to know more information about the Pseudotyped GFP HPV related products or other research materials, please visit Creative Diagnostics at https://www.creative-diagnostics.com/.

Creative Diagnostics
New York, USA

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers' assay development and manufacturing needs.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Creative Diagnostics Broadens Its Portfolio with New Pseudotyped GFP HPV here

News-ID: 2296139 • Views: 171

More Releases from Creative Diagnostics

Creative Diagnostics Launches Fluorescently Labeled Gold Nanoparticles for Cellu …
With years of experience in the pharmaceutical and life science sector, Creative Diagnostics introduces a series of fluorescently labeled gold nanoparticles for efficient cell uptake, such as DiagNano™ Fluorophore Labeled Gold Nanoparticles, 10 nm, Cellular Uptake(GFL-10-CU), and DiagNano™ Fluorophore Labeled Gold Nanoparticles, 50 nm, Cellular Uptake (GFL-50-CU). These new products can be potentially used for cancer diagnostics, studies, and immunoassays. Colloidal and intracellular gold nanoparticles can be validated by confocal microscopy.
Creative Diagnostics Introduces the Launch of Beta Actin Antibody
As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently expanded antibody portfolio with the launch of a series of beta actin antibody for ICC/IF, WB, and IHC-P. These new products are only for research use, and are not intended for diagnostic use. Creative Diagnostics offers primary antibodies to multiple forms of virtually every protein in the proteome, and secondary antibodies that are
Creative Diagnostics Supports COVID-19 Testing with Antigen Lateral Flow Assay D …
As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics now introduces COVID-19 Antigen Lateral Flow Assay Development, including the SARS-CoV-2 nucleoprotein antibody pair for rapid COVID-19 antigen assays to equip healthcare workers for rapid COVID-19 antigen detection. Additionally, Creative Diagnostics also offers SARS-CoV-2 antigen extraction buffer tubes that can be used as packing supplies for SARS-CoV-2 antigen extraction. The global COVID-19 pandemic has
ACE2 Products Are Available at Creative Diagnostics to Advance SARS-CoV-2 Resear …
With COVID-19 rapidly spreading globally, scientists all over the world are devoted to related researches, trying to find an effective vaccine or drug to stop this epidemic. Angiotensin-converting enzyme 2 (ACE2) is an integral membrane protein with considerable homologous to ACE, which belongs to the peptidase M2 family. In case of human coronaviruses SARS and HCoV-NL63 infections, ACE-2 serves as a functional receptor for the spike glycoprotein of both coronaviruses.

All 5 Releases


More Releases for HPV

HPV Vaccines Market 2020-2026 - COVID19 Impact On HPV Vaccines Industry | Top Ke …
HPV Vaccines Market Size, Share & Industry Analysis, By Type (Bivalent and Polyvalent), By Disease Indication (HPV Associated Cancer and Genital Warts), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others) and Geography Forecast, 2019-2026. Get Sample Copy Of Report To Know The Impact of Covid19 on this Industry: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/human-papillomavirus-hpv-vaccines-market-101962 Top Key Players: GSK, Merck. An Overview of the Impact of COVID-19 on HPV Vaccines Market: The emergence of COVID-19 has brought
Cytology and HPV Testing Market - Research Analysis
The nature of the both the markets for cytology testing and HPV or human papillomavirus testing is oligopolistic in nature, states Transparency Market Research (TMR) in a research report. With the presence of only a handful of leading companies in the market, the competition is not that high as they compete among themselves with different or almost similar strategies. These few players are currently enjoying their reign in the global
Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017
"The Report Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape. Human papillomavirus (HPV) is the most common viral infection
Cytology and HPV Testing Market: Disparate Levels of Awareness among Patients Re …
Over the years, the level of awareness among the global population regarding the various types of cancer has increased tremendously. The significance of early detection and diagnosis is not lost on them, resulting in the increased adoption of screening tests such as cytology and human papillomavirus (HPV) testing. The global market for cytology and HPV testing is presented with a host of sustained growth opportunities arising mainly from several emerging economies,
HPV Testing Market 2017- Qiagen, Roche Diagnostics, Hologic
HPV Testing Market 2017 Industry research report provides important information to identify and analyze the market need, market size and competition. This market research report used in maintaining competitiveness over competitors. “The human papillomavirus (HPV) test detects the presence of human papillomavirus, a virus that can lead to the development of genital warts, abnormal cervical cells or cervical cancer. The HPV testing is further classified into three sub-segments, namely, follow-up testing,
New Research: Global Human Papillomavirus (HPV) Market
MarketResearchReports.Biz presents this most up-to-date research on "Human Papillomavirus (HPV)- Epidemiology Forecast To 2023" Latest Report, Human Papillomavirus (HPV) - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Human Papillomavirus (HPV) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Human Papillomavirus (HPV) prevalent or incident cases segmented by age, sex and subpopulations. The